Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Efanesoctocog alfa is a factor VIII fusion agent that permits weekly treatment to prevent bleeding. In this study, two thirds of treated patients had no bleeding episodes, and the annualized bleeding rate fell by 77%.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-01, Vol.388 (4), p.310-318
Hauptverfasser:	von Drygalski, Annette, Chowdary, Pratima, Kulkarni, Roshni, Susen, Sophie, Konkle, Barbara A., Oldenburg, Johannes, Matino, Davide, Klamroth, Robert, Weyand, Angela C., Jimenez-Yuste, Victor, Nogami, Keiji, Poloskey, Stacey, Winding, Bent, Willemze, Annemieke, Knobe, Karin
Format:	Artikel
Sprache:	eng
Schlagworte:	Bleeding Body weight Chemoprevention Childhood Diseases Coagulants - administration & dosage Coagulants - therapeutic use Coagulation Coagulation factors Disease prevention Drug Administration Schedule Factor VIII - administration & dosage Factor VIII - therapeutic use Genetics Genetics General Half-Life Hematology Hemophilia Hemophilia A - complications Hemophilia A - drug therapy Hemorrhage - drug therapy Hemorrhage - etiology Hemorrhage - prevention & control Humans Life Sciences Oncology Pain Patients Pediatrics Pharmacokinetics Population studies Prophylaxis Quality of life Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Surgery Von Willebrand factor von Willebrand Factor - administration & dosage von Willebrand Factor - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Efanesoctocog alfa is a factor VIII fusion agent that permits weekly treatment to prevent bleeding. In this study, two thirds of treated patients had no bleeding episodes, and the annualized bleeding rate fell by 77%.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2209226